Responses in children to measles vaccination associated with perirenal transplantation

Mori, Kazuetsu; Kawamura, Ken; Honda, Masashi; Sasaki, Nozomu

doi:10.1111/j.1442-200x.2009.02816.x

Cited by 11 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MMR vaccine has been given to infants awaiting renal transplantation with good responses [104,105]. Children who are transplant candidates and not yet vaccinated with MMR should be vaccinated unless transplantation is imminent.…”

mentioning

confidence: 99%

Vaccination of immunocompromised patients

Ljungman

2012

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Clin Microbiol Infect 2012; 18 (Suppl. 5): 93–99 Abstract Vaccination of immunocompromised patients is challenging both regarding efficacy and safety. True efficacy data are lacking so existing recommendations are based on immune responses and safety data. Inactivated vaccines can generally be used without risk but the patients who are most at risk for infectious morbidity and mortality as a result of their severely immunosuppressed state are also those least likely to respond to vaccination. However, vaccination against pneumococci, Haemophilus influenzae and influenza are generally recommended. Live vaccines must be used with care because the risk for vaccine‐associated disease exists.

show abstract

mentioning

confidence: 99%

Vaccination of immunocompromised patients

Ljungman

2012

Clinical Microbiology and Infection

View full text Add to dashboard Cite

show abstract

“…Pre-transplantation immunization against measles has been shown to be safe, with seroconversion rates ranging from 80% to 98%. [82][83][84] The fact that measles pretransplantation titers are predictive of post-transplantation titers 13 confirms the importance to ensure adequate immunization before SOT. With respect to post-transplant immunization, only 4 prospective studies have evaluated carefully selected children immunization after SOT.…”

Section: Measles-mumps-rubellamentioning

confidence: 72%

Immunizations in solid organ and hematopoeitic stem cell transplant patients: A comprehensive review

L'Huillier

Kumar

2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The Solid Organ Transplantation (SOT) and Haematopoietic Stem Cell Transplantation (HSCT) population is continuously increasing as a result of broader indications for transplant and improved survival. Infectious diseases, including vaccine-preventable diseases, are a significant threat for this population, primarily after but also prior to transplantation. As a consequence, clinicians must ensure that patients are optimally immunized before transplantation, to provide the best protection during the early post-transplantation period, when immunosuppression is the strongest and vaccine responses are poor. After 3-6 months, inactivated vaccines immunization can be resumed. By contrast, live-attenuated vaccines are lifelong contraindicated in SOT patients, but can be considered in HSCT patients at least 2 years after transplantation, if there is no immunosuppression or graft-versus-host-disease. However, because of the advantages of live-attenuated over inactivated vaccines--and also sometimes the absence of an inactivated alternative--an increasing number of prospective studies on live vaccine immunization after transplantation are performed and give new insights about safety and immunogenicity in this population.

show abstract

“…A genetic component to explain differences in antibody production between individuals in response to MMR vaccination has been suggested [46,47]. The MMR vaccine has been shown to be immunogenic in transplant candidates and no serious adverse events have been reported Review article: Medical intelligence [4,48,49]. In SOT recipients, however, but only in small paediatric studies (N ≤35), the seroconversion rate was lower after SOT (range 41-100% for the measles component) but appeared to be safe in specific conditions, which included low immunosuppression (table 3) [27,32,33,35,36,50].…”

Section: Measles Mumps and Rubella Vaccinementioning

confidence: 99%

Live viral vaccines in transplanted patients

L'Huillier

2014

Swiss Med Wkly

View full text Add to dashboard Cite

Live attenuated viral vaccines (LAVV) have been used safely and with great success for decades to protect healthy patients against sometimes life-threatening diseases. The current recommendations usually contraindicate their use in immunocompromised hosts, despite an often increased risk for a severe presentation of disease. In this article, we review currently available LAVV, such as varicella-zoster, measles/mumps/rubella, influenza, polio, rotavirus, and yellow fever in patients with solid organ or haematopoietic stem cell transplantation. The current paediatric and adult experience with pre- and post-transplantation vaccination is discussed. To date, because of insufficient data, evidence-based recommendations to safely vaccinate transplant recipients are not available. Hopefully in the near future, specific recommendations will be implemented for certain LAVV in these patients.

show abstract

Responses in children to measles vaccination associated with perirenal transplantation

Abstract: Live measles vaccination of children with chronic renal failure is effective and safe, because the seroconversion rate, rate of antibody titer maintenance and degree of antibody titer elevation in children with chronic renal failure were all equivalent to those of healthy children.

Cited by 11 publications

References 15 publications

Vaccination of immunocompromised patients

Vaccination of immunocompromised patients

Immunizations in solid organ and hematopoeitic stem cell transplant patients: A comprehensive review

Live viral vaccines in transplanted patients

Contact Info

Product

Resources

About